/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Enzon Pharmaceuticals, Inc. (together with its subsidiaries, the Company, Enzon, we or us ) is positioned as a public company acquisition vehicle. Historically, we have received royalty revenues from licensing arrangements with other companies primarily related to sales of certain drug products that utilized Enzon s proprietary technology.
$4.71
+$0.06 (+1.29%)
Price from 48 days ago
Free cash flow declined 368% versus the prior year, cash generation momentum has weakened. ROIC dropped from -32.19% to -278.97%, capital efficiency is deteriorating.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$14M
▼ -538.2% YoY
Op. Margin
—
ROIC
2.16%
▼ -246.8pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$33M
▼ -368.3% YoY
Op. Cash Flow (TTM)
-$33M
▼ -368.3% YoY
Net Debt
$196M
Cash & Equiv.
$8M
5Y CAGR: -67.3%
Continue Research
SourceComputed from the 10-Q filed 3 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 4 Aug 2026. How this is calculated.
Price from market data, last close as of 30 Jul 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.
Viskase Holdings (ENZN)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in .
On quality, Viskase Holdings scores 0/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. It currently yields about 1.9%; see dividend safety for coverage and history. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Viskase Holdings scores 0 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a 2.2% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Yes, Viskase Holdings pays a regular dividend of about $0.09 per share per year (typically in quarterly installments), a yield of roughly 1.9% at the current price. A low headline yield is not the same as a weak dividend: what matters is how well earnings and free cash flow cover the payout and whether it is growing, not the percentage alone. For ENZN's full payout history, growth streak and dividend-safety score, see the dividends tab.
That depends on valuation and quality together, not either alone. you should weigh ENZN's valuation and scores 0/100 on quality (lower-quality). It also yields about 1.9%. A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.